ANDEXANET ALFA VS NON-SPECIFIC TREATMENTS FOR INTRACEREBRAL HEMORRHAGE IN PATIENTS TAKING FACTOR XA INHIBITORS - INDIVIDUAL PATIENT DATA ANALYSIS OF ANNEXA-4 AND TICH-NOAC.

Bernhard Matthias Siepen Alexandros A Polymeris Ashkan ShoamaneshStuart ConnollyThorsten Steiner Sven PoliRobin LemmensMartina Béatrice GoeldlinMadlaine MüllerMattia BrancaJanis RauchThomas MeinelJohannes KaesmacherWerner J Z'GraggenMarcel ArnoldUrs FischerNils PeterStefan T EngelterPhilippe A LyrerDavid Julian Seiffge

Published in: International journal of stroke : official journal of the International Stroke Society (2024)

Use of andexanet alfa compared to any other non-specific treatment strategy was associated with decreased odds for hematoma expansion, without increased odds for thromboembolic complications.

Keyphrases

end stage renal disease
replacement therapy
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
electronic health record
risk factors
artificial intelligence
patient reported
smoking cessation